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Curcuma longa has long been used in China and India as anti-inflammatory agent to
treat a wide variety of conditions and also as a spice for varied curry preparations. The
chemoprofile of the Curcuma species exhibits the presence of varied phytochemicals
with curcumin being present in all three species but AA only being shown in C. longa.
This study explored the effect of a curcumin/AA combination on human cancer cell lines.
The curcumin/AA combination was assessed by isobologram analysis using the Loewe
additivity drug interaction model. The drug combination showed additive cytotoxicity
toward CCRF-CEM and CEM/ADR5000 leukemia cell lines and HCT116p53+/+ and
HCT116p53−/− colon cancer cell line, while the glioblastoma cell lines U87MG
and U87MG.1EGFR showed additive to supra-additive cytotoxicity. Gene expression
profiles predicting sensitivity and resistance of tumor cells to induction by curcumin
and AA were determined by microarray-based mRNA expressions, COMPARE, and
hierarchical cluster analyses. Numerous genes involved in transcription (TFAM, TCERG1,
RGS13, C11orf31), apoptosis-regulation (CRADD, CDK7, CDK19, CD81, TOM1) signal
transduction (NR1D2, HMGN1, ABCA1, DE4ND4B, TRIM27) DNA repair (TOPBP1,
RPA2), mRNA metabolism (RBBP4, HNRNPR, SRSF4, NR2F2, PDK1, TGM2), and
transporter genes (ABCA1) correlated with cellular responsiveness to curcumin and
ascorbic acid. In conclusion, this study shows the effect of the curcumin/AA combination
and identifies several candidate genes that may regulate the response of varied cancer
cells to curcumin and AA.
Keywords: drug interaction, isobologram analysis, pharmacogenomics, phytotherapy, synergism
INTRODUCTION
Curcuma longa L. belongs to the family Zingiberaceae, which is a perennial herb that measures up
to 1m height with a short stem. It is distributed throughout tropical and subtropical regions in
the world, being widely cultivated in Asian countries, mainly in India and China (Kapoor, 1990).
As a component of folklore medicine the use of C. longa has been documented both in Indian
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and Chinese cultures. The rhizomes are used as Ezhu according
to the Chinese Pharmacopoeia (2010 edition; Zhao et al., 2010)
and are a household remedy in Nepal (Eigner and Scholz,
1999). The long list of usages include antiseptic, analgesic, anti-
inflammatory, antimalarial, and insect repellant (Chaudhri, 1950;
Li et al., 1998; Niederau and Göpfert, 1999; 2001; Tawatsin et al.,
2001; Duke, 2002). Traditional Indian medicine claims to use
its powder against biliary disorders, anorexia, coryza, cough,
diabetic wounds, hepatic disorders, rheumatism, and sinusitis
(Ammon et al., 1992). In ancient Hindu medicine, C. longa is
extensively used for the treatment of sprains and swelling caused
by injury (Ammon and Wahl, 1991). The antioxidant activity of
C. longa is well-known (Ammon and Wahl, 1991; Anand et al.,
2007).
Extensive research during the past years revealed that
curcumin has considerable potential against a wide variety of
both malignant and non-malignant diseases. Curcumin exhibits
activity against numerous inflammatory diseases, including
pancreatitis (Gukovsky et al., 2003; Gülçubuk et al., 2005),
arthritis (Joe et al., 1997; Liacini et al., 2002), inflammatory
bowel disease (Holt et al., 2005), gastritis (Swarnakar et al., 2005),
allergy (Baek et al., 2003; Ram et al., 2003), and fever (Lee et al.,
2003; Shao et al., 2004), possibly through the downregulation
of inflammatory markers. It is also active against autoimmune
diseases, including scleroderma (Tourkina et al., 2004), psoriasis
(Bosman, 1994), multiple sclerosis (Verbeek et al., 2005), and
diabetes (Babu and Srinivasan, 1995, 1997; Sajithlal et al., 1998).
Curcumin also exhibits a great potential against various types of
cancers. Its mechanism of action involves, firstly, the suppression
of tumor cell proliferation by down-regulation of anti-apoptotic
gene products, activation of caspases, and induction of tumor
suppressor genes (Jiang et al., 1996; Bush et al., 2001; Chan and
Wu, 2004). Secondly, curcumin suppresses tumor invasion by
down-regulation of matrix metalloproteinases and cell surface
adhesion molecules (Lin et al., 1998; Fenton et al., 2002; Lee et al.,
2006). Thirdly, curcumin inhibits angiogenic cytokines leading to
suppression of angiogenesis (Shin et al., 2001; Leyon and Kuttan,
2003; Bobrovnikova-Marjon et al., 2004) and lastly the anti-
inflammatory and cytotoxic effects of curcumin contribute to
its antitumor activity (Srivastava, 1989; Fujiyama-Fujiwara et al.,
1992; Ammon et al., 1993).
The activity of many medicinal plants results from
the interaction action of several constituents, which may
cooperatively act in an additive or synergistic manner. It has
been repeatedly observed that extracts of medicinal plants
reveal better activities than their isolated single compounds at
comparable equivalent concentrations of the active components.
This phenomenon is attributed to the absence of interacting
substances present in crude extracts. For example, extracts were
obtained from the fresh herb of Artemisa annua L. either by
soaking the herb in water followed by wringing out the juice
by hand or by pounding the fresh herb to a pulp followed by
squeezing out the juice. The extracts were then analyzed for
artemisinin concentration and tested against malaria parasites.
Abbreviations: AA, ascorbic acid; IC50, 50% inhibitory concentration; NCI,
National Cancer Institute.
It was found that the antiplasmodial IC50-values were 6–18-fold
lower than was expected in terms of their artemisinin content
suggesting that the activity of the extracts could not be entirely
accounted by their artemisinin content (Wright et al., 2010).
Another example are the Cinchona alkaloids. There are almost
30 alkaloids described in the bark of Cinchona officinalis L. The
most well-known of these are quinine, quinidine, and cinchonine
and cinchonidine. However, quinine is not the most potent of the
alkaloids: quinidine, dihydroquinidine, and cinchonine all have
consistently lower 50% inhibitory concentrations (IC50) in vitro.
The combination of quinine with quinidine and cinchonine
is 2–10 times more effective in vitro against quinine-resistant
strains, and the mixture of alkaloids reveals more consistent
effects than any of the alkaloids singly used (Druilhe et al., 1988;
Karle and Bhattacharjee, 1999). In pharmacokinetic synergy,
substances with little or no bioactivity may assist the main active
principle to reach the disease target by several mechanisms,
e.g., improving bioavailability, or decreasing metabolism and
excretion. Comparable effects are not yet known for C. longa
and needs to be elucidated. In the present investigation, we
addressed this question. We have chosen ascorbic acid (vitamin
C, ascorbate, C6H12O6) as phytochemical constituent of C. longa
to investigate the additive or synergistic effects of its combination
with curcumin.
Ascorbic acid is a ketolactone and a water-soluble antioxidant.
There are two chemical forms of ascorbic acid: the reduced form
(ascorbic acid; AA) and the oxidized form (dehydroascorbic acid;
DHA; Mamede et al., 2011). AA is well-known for its potent
antioxidant properties, as it is able to scavenge free radicals and
reactive oxygen species (ROS). Thus, it has been associated with
decreased oxidative stress in vivo (Carr A. and Frei, 1999; Carr A.
C. and Frei, 1999). High doses of AA can reduce inflammatory
biomarkers such as C-reactive protein (CRP), tumor necrosis
factor (TNF-α), interferon-γ (IFN-γ), and the interleukins IL-
1, IL-2, IL-6, IL-8 (Gilliam and St Clair, 2011; Mikirova
et al., 2012). AA is a cofactor in vivo for enzymes involved
in the biosynthesis of collagen, carnitine, neurotransmitters,
and neuropeptide hormones as well as enzymes involved in
regulation of epigenetic or transcription factors (Rebouche,
1991; Du et al., 2012). Furthermore, it is a cofactor in the
synthesis of the neurotransmitters norepinephrine, dopamine,
and serotonin and neuropeptide hormones such as oxytocin
(Harrison and May, 2009; May et al., 2012). Extensive studies
have been carried out on AA in the treatment of cancer and
vast literature exists on AA and cancer. In 1949, AA was first
proposed to be used for cancer therapy (Klenner, 1949; Mc,
1952). The first comprehensive review on AA and cancer was
published in 1979 and an updated review 25 years later (Cameron
et al., 1979; González et al., 2005). AA may act as a prodrug
causing the formation of AA radical and hydrogen peroxide
in the extracellular space (Chen et al., 2007). In a clinical
trial, AA exerted antitumor activity in patients with advanced
cancer as a stand-alone therapy as well as in combination with
other anticancer agents (Hoffer et al., 2008). The conjugation
of AA with extracts of medical herbs stimulated apoptosis and
disrupted the cell cycle in different cancer cell lines. Furthermore,
AA was pro-oxidant generating hydrogen peroxide-dependent
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cytotoxicity toward various cancer cells without adversely
affecting normal cells. AA together with sodium nitrite induced
genotoxicity due to oxidative DNA damage. High concentrations
of AA killed tumor cells in vitrowith high efficiency and inhibited
angiogenesis inmice bearing sarcoma (Chen et al., 2008; Kuroiwa
et al., 2008; Verrax and Calderon, 2009; Yeom et al., 2009;
Rozanova Torshina et al., 2010).
In this paper, we have chosen AA because it is widely
distributed in many plants and it is also synthetically available.
This allows us to investigate the cytotoxicity of the combination
of curcumin and AA outside of the plant at exactly defined
conditions to clarify their pharmacological effects in the
combination. Our strategy was to investigate the combination
by isobologram analysis and to investigate the genes which are
related to the cytotoxicity induced by curcumin and AA in a
broad spectrum of cancers. We postulate that the identification
of genes that are specifically regulated by AA and curcumin could
improve the understanding of the efficacy of C. longa in cancer
treatment. We have systematically studied the microarray-based
mRNA expression of genes, which influence the cellular response
to curcumin and AA in the tumor cell line panel of the National
Cancer Institute (NCI), USA to find possible mechanistic
explanations for the interaction of these two compounds.
MATERIALS AND METHODS
Chemicals
All chemicals were of analytical grade. Curcumin, AA andDMSO
were purchased from Sigma-Aldrich (Sigma-Aldrich Corp., St.
Louis, MO, USA).
COMPARE and Hierarchical Cluster
Analyses of Microarray Data
The cancer cell lines of the Developmental Therapeutics Program
of NCI consisted of a series of non-small cell lung cancer,
colon cancer, renal cancer, ovarian cancer cells, leukemia,
melanoma, prostate carcinoma, breast cancer, and tumor cells
of the central nervous system. Their origin and processing have
been previously reported (Alley et al., 1988). The cytotoxicity
induced by AA, curcumin, and standard anticancer drugs of
the NCI cell line panel was measured by the sulforhodamine B
assay. The 50% inhibition concentrations calculated from dose-
response curves and converted to logarithmic values [log10IC50
(M)] have been deposited at the NCI database (http://dtp.
cancer.gov/databases_tools/default.htm). ThemRNAmicroarray
hybridization of the NCI cell lines has been reported and
deposited at the NCI website (http://dtp.cancer.gov/databases_
tools/default.htm). COMPARE analyses were performed to
produce rank ordered lists of genes expressed in the NCI cell
lines. The methodology has been previously described in detail
as a tool to identify candidate genes for drug resistance and
sensitivity. To derive COMPARE rankings, a scale index of
correlation coefficients (R-values) was created from log10IC50
(M) values of test compounds and microarray-based mRNA
expression values. Greater mRNA expression correlated with
enhanced drug resistance in the standard COMPARE approach,
whereas greater mRNA expression in cell lines indicated drug
sensitivity in reverse COMPARE analyses. Pearson’s correlation
test was used to calculate significance values and rank correlation
coefficients as a relative measure for the linear dependency of two
variables.
For hierarchical cluster analysis, objects were classified by
calculation of distances according to the closeness of between
individual distances by means of hierarchical cluster analysis.
All objects were assembled into cluster trees (dendrograms).
Merging of objects with similar features leads to cluster
formation, where the length of the branch indicates the degree
of relation. Distances of subordinate cluster branches to superior
cluster branches serve as criteria for the closeness of clusters.
Thus, objects with tightly related features were clustered closely
together, while separation of objects in the dendrogram increased
with progressive dissimilarity. Hierarchical clustering and heat-
map analysis were performed using Euclidean distance and ward
method implemented in “dist,” “hclust,” and “heatmap” functions
in R programming (Eisen et al., 1998; Gu et al., 2016). The results
were further confirmed using the CIM miner software by use of
the one matrix clustered image map (CIM) https://discover.nci.
nih.gov/cimminer/oneMatrix.do.
Cell Culture
Drug sensitive CCRF-CEM and multidrug-resistant P-
glycoprotein overexpressing CEM/ADR5000 leukemic cells
were generously provided by Prof. Axel Sauerbrey (Department
of Pediatrics, University of Jena, Jena, Germany). They were
cultured in RPMI-1640 medium supplemented with 10%
FBS and 1% penicillin/streptomycin (Invitrogen, Darmstadt,
Germany). Doxorubicin (5000 ng/mL) was added to maintain
overexpression of P-gp (MDR1, ABCB1) in resistant cells
(Kimmig et al., 1990). Human wild-type HCT116 colon cancer
cells (p53+/+) and knockout clones (p53−/−) derived by
homologous recombination (Waldman et al., 1995; Bunz et al.,
1998) were generously provided by Dr. B. Vogelstein and H.
Hermeking (Howard Hughes Medical Institute, Baltimore, MD,
USA). Both colon cancer cells were cultured in DMEM medium
supplemented with 10% FBS and 1% penicillin/streptomycin
(Invitrogen). Wild-type human U87MG glioblastoma multiform
cells and cells transfected with control mock vector or an
expression vector harboring EGFR cDNA with a deletion in
exons 2–7 (U87MG.1EGFR), were kindly provided by Dr. W. K.
Cavenee (Ludwig Institute for Cancer Research, San Diego, CA,
USA; Huang et al., 1997).
Cell Viability Assay
Cell viability was evaluated by resazurin assay. This test is
based on reduction of the indicator dye, resazurin, to the highly
fluorescent resorufin by viable cells. Nonviable cells rapidly lose
the metabolic capacity to reduce resazurin and thus produce
no fluorescent signal. Glioblastoma and colon cancer cells were
harvested with 0.25% trypsin/EDTA (Invitrogen, Germany) and
diluted to a final concentration 5 × 104 cells/mL. One hundred
microliters of the cell suspension were sowed into the wells
of a 96-well-culture plate 1 day before treatment. However,
for the leukemia cell lines 2 × 104 cells were sowed in a 96-
well-culture plate in a total volume of 100 µL for each well
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and then the cells were immediately treated. Marginal wells
were filled with 200 µL of pure medium, in order to minimize
effects of evaporation. Besides, wells filled with medium served
as the negative control to determine background fluorescence
that may be present. Then, cells were treated with different
concentrations of curcumin, vitamin C alone, or combined. After
72 h, 20 µL resazurin (Sigma-Aldrich, Germany) 0.01% w/v in
ddH2O was added to each well and the plates were incubated
at 37◦C for 4 h. Fluorescence was measured on an Infinite
M2000 Proplate reader (Tecan, Germany) using an excitation
wavelength of 544 nm and an emission wavelength of 590 nm.
Each assay was done at least two times, with six replicates
each. The cytotoxic effect of the treatment was determined as
percentage of viability and compared to untreated cells. The
calculated cell viability (y-axis) was plotted against the log drug
concentration (x-axis) usingMicrosoft Excel. The obtained curve
was used to determine the IC50-value, which represented the
concentration of the test compound required to inhibit 50% of
cell proliferation.
Statistical Analysis
The Loewe additivity model was used to calculate synergetic drug
interactions between curcumin and vitamin C in inhibiting cell
growth. In this model, the combination index (CI) was defined as
CI = (d1/D1)/(d2/D2), where D1 and D2 were the doses of drug
1 and drug 2 that produced an response Y (e.g., 50% inhibition
of CCRF-CEM growth) when used alone, d1 and d2 were the
doses of drug 1 and drug 2 in combination, which can generate
the same response Y. If the CI is equal, less than or more than 1,
the combination dose (d1, d2) is termed as additive, synergistic,
or antagonistic, respectively. The drug interaction was illustrated
geometrically as isobologram.
Pearson’s correlation test was used to calculate significance
values and rank correlation coefficients as a relative measure
for the linear dependency of two variables. This test was
implemented into theWinSTATProgram (Kalmia Co.). Pearson’s
correlation test determined the correlation of rank positions of
values. Ordinal or metric scaling of data is suited for the test and
transformed into rank positions. There is no condition regarding
normal distribution of the data set for the performance of this
test. We used Pearson’s correlation test to correlate microarray-
based mRNA expression of candidate genes with the IC50-values
for curcumin and ascorbic acid.
The χ2-test was applied to bivariate frequency distributions
of pairs of nominal scaled variables. It was used to calculate
significance values (p-values) and rank correlation coefficients
(R-values) as a relative measure for the linear dependency of
two variables. This test was implemented into the WinSTAT
program (Kalmia Co.). The χ2-test determines the difference
between each observed and theoretical frequency for each
possible outcome, squaring them, dividing each by the theoretical
frequency, and taking the sum of the results. Performing the
χ2-test necessitated to define cell lines as being sensitive or
resistant to curcumin and ascorbic acid. This has been done by
taking the median IC50-value (log10 = −5.1 M) for curcumin
and IC50-value (log10 = −2.7 M) for ascorbic acid as a cut-off
threshold.
RESULTS
Chemoprofiling of Different Curcuma
Species
As a first step, we established chemoprofiles of three Curcuma
species (C. longa, C. zedoaria, and C. xanthorrhiza) based on
the chemical compositions of these species deposited at Dr.
Duke’s Phytochemical and Ethnobotanical Databases (http://
www.arsgrin.gov/cgi-bin/duke/farmacy2.pl). We subjected the
chemical composition of these plants to hierarchical cluster
analysis (Figure 1). A total of 114 phytochemicals have
been included in the analysis, which are listed in detail in
Supplementary Table 1. Three compounds were commonly
found in all three Curcuma species (curcumin, D-camphor, and
desmethoxycurcumin). Ten compounds were found in two of
the three species, whereas all other compounds were found
in only one Curcuma species. This specific distribution of
phytochemicals enables specific clustering and separation of the
Curcuma species.
Cytotoxicity of AA in the NCI panel of Cell
Lines
We hypothesized that the cytotoxic effect of C. longa against
cancer cells is not solely caused by its main compound, curcumin,
but that other compounds may also contribute to this activity of
the plant. To prove this hypothesis, we mined the NCI database
for compounds found in C. longa and six compounds were
identified (Figure 2A), i.e., AA, limonene, guaiacol, p-cymene,
azulene, and curcumin. Although AA was not the most toxic
compound among the six tested, we decided to continue our
investigations with AA, because of its far distribution not only in
C. longa but also in many other plants as well and it’s enormous
relevance for human health in general. Further, investigations
were then carried out using AA in the NCI panel of cell lines.
Leukemia and melanoma cell lines were most sensitive, while
brain and lung cancer cell lines were the most resistant ones
(Figure 2B). Established anticancer drugs frequently show high
sensitivity toward leukemia, but resistance toward melanoma.
Hence, it is interesting that AA was active against melanoma cell
lines.
Cytotoxicity of Curcumin and AA toward
Drug Resistant Cancer Cell Lines
Drug-resistant cell lines with different resistance mechanisms
(P-glycoprotein, EGFR, mutant p53) toward curcumin and AA
were determined. All the cell lines were treated with varying
concentrations of curcumin and AA for 72 h, their growth
was inhibited in a dose-dependent manner, albeit at different
efficacy. The IC50-values were calculated from the dose response
curves and summarized in Table 1. Curcumin inhibited cell
growth at lower concentrations than AA. The range of IC50-
values was 5.22–58.3 µM for curcumin, while that of AA
was 389.1–561.2 µM. The CCRF-CEM and CEM/ADR5000
leukemia cell lines were inhibited at concentrations of 5.22
and 6.33 µM, respectively. The U87MG.1EGFR-transfectant
glioblastoma cells exhibited sensitivity toward curcumin with
an IC50-value of 46.1 µM, which was slightly lower than the
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FIGURE 1 | Dendrogram obtained by hierarchical cluster analysis of phytochemical constituents of Curcuma longa, C. zedoaria, and C. xanthorrhiza.
The chemical compounds included in this cluster analysis are listed in detail in Supplementary Table 1.
FIGURE 2 | (A) Mean IC50 log10-values of selected cytotoxic phytochemicals
from Curcuma longa for the NCl tumor cell line panel as assayed by the
sulforhodamine B-test. (B) Tumor-type-dependent cytotoxicity of ascorbic
acid. Insert, chemical structure of ascorbic acid.
IC50-value of wild-type U87MG cells 49.6 µM. Interestingly,
the HCT166p53−/− colon cancer cell line was preferentially
inhibited by AA with an IC50-value of 506.9 µM compared
to HCT116p53+/+ wild-type cells 561.2 µM. The degrees of
resistance were calculated by dividing the IC50 of the resistant
cell line by the IC50 of the sensitive cell line. Compared
to the high degrees of resistance of these drug-resistant cell
lines to standard drugs such as doxorubicin (Hall et al.,
2009), curcumin and AA inhibited these cell lines with similar
efficacies. The degrees of resistance were in a range of 0.9–1.41
(Table 1).
Cytotoxic Effects of Combination
Treatments of Curcumin and AA
Next, we addressed the question, whether the combination
of curcumin and AA exhibits additive or synergistic growth
inhibition of cancer cells. We applied a universal reference
TABLE 1 | IC50-values of curcumin and vitamin C toward various cell lines.
Cell lines Curcumin Vitamin C
IC50 (µM) Degree of
resistance
IC50 (µM) Degree of
resistance
CCRF-CEM 5.22 ± 0.15 502.61 ± 2.24
CEM/ADR5000 6.33 ± 0.07 1.21 523.12 ± 2.19 1.04
U87MG 49.60 ± 16.40 389.10 ± 53.50
U87MG.1EGFR 46.10 ± 4.80 0.92 532.10 ± 76.40 1.37
HCT116p+/+ 41.20 ± 12.06 561.20 ± 58.80
HCT116p53−/− 58.30 ± 4.30 1.41 506.90 ± 20.40 0.90
Shown are mean values ± SD of four independent experiments with each six parallel
measurements. Degrees of resistance were calculated by the IC50 resistant cell line/IC50
sensitive cell line ratio.
model for evaluating the effects of drug interaction, i.e., the
Loewe additivity model (isobologram analysis). The cancer
cell lines were treated with varying concentrations of AA at
indicated concentrations of curcumin for 72 h. In CCRF-
CEM and CEM/ADR5000 cells, the IC50-values of curcumin
in combination with AA were reduced by less than half of
the IC50 of curcumin alone. In the glioblastoma and colon
cancer cell lines, the IC50-value of two of the curcumin
concentrations (20% IC50 curcumin and 40% IC50 curcumin)
decreased with increasing AA concentrations less than the IC50
of curcumin alone. However, the two other concentrations
of curcumin reduced the IC50 in combination with AA by
less than half of the IC50-value of curcumin alone. Dose-
normalized IC50 isobolograms for all cell lines were generated
by plotting the combination treatment IC50-values of curcumin
against AA. Additive effects were observed in CCRF-CEM and
CEM/ADR5000 (Figure 3) as well as in HCT116p53+/+ and
HCT116p53−/− cell lines (Figure 4), whereas supra/additive
effects were visible in U87MG and U87MG.1EGFR cells
(Figure 5).
COMPARE and Hierarchical Cluster
Analyses of mRNA Expressions
The transcriptome-wide mRNA expression of the NCI cell lines
based on the Novartis microarray platform was investigated
by COMPARE analyses and correlated to the log10IC50 (M)
values for curcumin and AA. This bioinformatical approach
was performed to identify novel putative factors associated
with cellular response to curcumin and AA. The top 20 genes
with direct and top 20 genes with inverse correlation co-
efficient are shown in Tables 2, 3. These genes were subjected to
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FIGURE 3 | Isobologram analysis for the interaction of various
combinations of curcumin and ascorbic acid on (A) CCRF-CEM and
(B) CEM/ADR5000 leukemia cell lines.
hierarchical cluster analysis to analyze, whether the expression
profiles of these genes may predict sensitivity or resistance
of the cells to curcumin and AA. The mRNA expression
of the identified genes were subjected to hierarchical cluster
analysis and cluster image mapping (Figures 6, 7). The resulting
dendogram with the cell lines analyzed on the left can be divided
into five major clusters for curcumin and four clusters for
ascorbic acid. Using the chi-square test, we analyzed whether
the distribution of cell lines being sensitive or resistant to
curcumin and AA was statistically significant. As shown in
Table 4, the distribution of sensitive or resistant cell lines on
the dendogram was significantly different indicating that cellular
response to curcumin or AA was predictable by the mRNA
expression of these genes. Therefore, it is interesting to know
the function of these genes. The specific functions of the
proteins encoded by the genes were diverse and included signal
transduction, transcription factors, proteasome deregulation,
apoptosis regulating genes, proliferation-related genes, pro-
as well as anti-oxidative genes (Tables 2, 3). AA induced
genes that belonged to the functional groups of transcription
factors (TFAM, TCERG1, RGS13, and C11orf31), apoptosis-
regulating genes (CRADD, CDK7, CDK19, CD81, TOM1) and
signal transduction genes (NR1D2, HMGN1, ABCA1, DE4ND4B,
TRIM27). Curcumin induction resulted in DNA repair genes
(TOPBP1, RPA2), mRNA metabolism genes (RBBP4, HNRNPR,
SRSF4, NR2F2, PDK1, and TGM2), signal transduction genes
(WWC1, DTX2, EGFR, CHRNB4, VPS41, CRIM1), proliferation-
related genes (RHOD), apoptosis-regulating genes (DFFB), and
transporter genes (ABCA1).
FIGURE 4 | Isobologram analysis for the interaction of various
combinations of curcumin and ascorbic acid on (A) HCT116p53+/+ and
(B) HCT116p53−/− colon cancer cell lines.
FIGURE 5 | Isobologram analysis for the interaction of various
combinations of curcumin and ascorbic acid on (A) U87MG and
(B) U87MG.∆EGFR glioblastoma cell lines.
DISCUSSION
Plants are perhaps earth’s most accomplished chemists. They
produce thousands of specialized secondary metabolites, and
during the evolution of life plants developed multi-targeted
chemicals to fulfill diverse tasks. C. longa contains some 30
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TABLE 2 | Meta-data of genes shown in the cluster analysis whose mRNA expression correlated with the log10IC50 values of curcumin in the NCI tumor
cell line panel.
Gene symbol Gene acc no. Gene name Gene function
ABCA1 AI344681 ATP-binding cassette, sub-family A (ABC1), member 1 cAMP-dependent and sulfonylurea-sensitive anion transporter. Key
gatekeeper influencing intracellular cholesterol transport.
AK2 U54645 Adenylate kinase 2 Catalyzes the reversible transfer of the terminal phosphate group
between ATP and AMP.
ALDH3B1 U10868 Aldehyde dehydrogenase 3 family, member B1 Oxidizes medium and long chain saturated and unsaturated aldehydes.
Protective role against the cytotoxicity induced by lipid peroxidation.
ANXA2P1 M62896 Annexin A2 pseudogene 1 Involved in cell proliferation and membrane physiology and is related to
cancer progression.
BAIAP2 AB015020 BAI1-associated protein 2 Adapter protein that links membrane-bound small G-proteins to
cytoplasmic effector proteins.
BAIAP2 AB015019 BAI1-associated protein 2 Adapter protein that links membrane-bound small G-proteins to
cytoplasmic effector proteins. Participates in actin bundling, if
associated with EPS8. Promoting filopodial protrusions.
BTFA1 AF038362 B-TFIID transcription factor-associated, 170kDa Regulates transcription in association with TATA binding protein (TBP).
Removes TBP from the TATA box.
CAPN2 M23254 Calpain 2 (m/II) large subunit Calcium-regulated non-lysosomal thiol-protease, which catalyzes
proteolysis of substrates involved in cytoskeletal remodeling and signal
transduction.
CHRNB4 U48861 Cholinergic receptor, nicotinic, beta 4 Leads to opening of an ion-conducting channel across the plasma
membrane.
CRIM1 AI651806 Cysteine rich transmembrane BMP regulator 1
(chordin-like)
Role in capillary formation and maintenance during angiogenesis.
DDX39B AC002400 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B Involved in nuclear export of spliced and unspliced mRNA. Assembling
component of the TREX complex. Has both RNA-stimulated ATP
binding/hydrolysis activity and ATP-dependent RNA unwinding activity.
DFFB AF064019 DNA fragmentation factor, 40kDa, beta polypeptide Induces DNA fragmentation and chromatin condensation during
apoptosis.
DT-UP-PM U38980 DTX2P1-UPK3BP1-PMS2P11 Encodes a putative E3-ubiquitin ligase with no known biological
function.
DTX2 AI138834 Deltex 2 Regulator of Notch signaling.
EGFR X00588 Epidermal growth factor receptor Receptor tyrosine kinase activating several signaling cascades.
Activates the NF-kappa-B signaling cascade.
EHD1 AF001434 EH-domain containing 1 Acts in early endocytic membrane fusion and membrane trafficking of
recycling endosomes.
HNRNPR AF000364 Heterogeneous nuclear ribonucleoprotein R Component of ribonucleosomes, which are complexes of >20 other
heterogeneous nuclear ribonucleoproteins (hnRNP). hnRNP play an
important role in processing of precursor mRNA in the nucleus.
IQCB1 D25278 IQ motif containing B1 Involved in ciliogenesis.
MTHFD2 X16396 Methylenetetrahydrofolate dehydrogenase (NADP+
dependent) 2
Encodes a nuclear-encoded mitochondrial bifunctional enzyme with
methylenetetrahydrofolate dehydrogenase and
methenyltetrahydrofolate cyclohydrolase activities.
NFATC2IP AA152202 Nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 2 interacting protein
In T-helper 2 (Th2) cells, regulates NFAT-driven transcription of cytokine
genes IL3, IL4, IL5 and IL13. Recruits PRMT1 to the IL4 promoter and
facilitates subsequent histone acetylation at the IL4 locus. Promotes
robust cytokine expression. Down-regulates formation of poly-SUMO
chains by UBE2I/UBC9.
NR2F2 M64497 Nuclear receptor subfamily 2 Ligand-activated transcription factor. Activated by high concentrations
of 9-cis-retinoic acid and all-trans-retinoic acid, but not by
dexamethasone, cortisol or progesterone (in vitro). Regulation of the
apolipoprotein A-I gene transcription.
PDK1 L42450 Pyruvate dehydrogenase kinase, isozyme 1 Role in regulation of glucose and fatty acid metabolism and
homeostasis via phosphorylation of the pyruvate dehydrogenase
subunits PDHA1 and PDHA2. Role in cellular responses to hypoxia.
Important for cell proliferation under hypoxia.
PLEKHM1 AB002354 Pleckstrin homology domain containing, family M (with
RUN domain) member 1
Involved in vesicular transport in the osteoclast. Role in
sialyl-lex-mediated transduction of apoptotic signals.
(Continued)
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TABLE 2 | Continued
Gene symbol Gene acc no. Gene name Gene function
POLR2L N24355 Polymerase (RNA) II (DNA directed) polypeptide L DNA-dependent RNA polymerase catalyzes the transcription of DNA
into RNA using the four ribonucleoside triphosphates as substrates.
PRPF4B U48736 Pre-mRNA processing factor 4B Role in pre-mRNA splicing. Phosphorylates SF2/ASF.
PSMG1 AJ006291 Proteasome (prosome, macropain) assembly
chaperone 1
Chaperone protein, which promotes assembly of the 20S proteasome
as part of a heterodimer with PSMG2.
RBBP4 X74262 Retinoblastoma binding protein 4 Core histone-binding subunit that may target chromatin assembly
factors, chromatin remodeling factors and histone deacetylases to their
histone substrates.
RBMX2 AL050405 RNA binding motif protein, X-linked 2 Encodes RNA binding motif protein, X-linked 2.
RHOD U61374 Ras homolog family member D Involved in endosome dynamics. Coordinates membrane transport
with the function of the cytoskeleton.
RPA2 J05249 Replication protein A2 Required for DNA recombination, repair and replication. Required for
the recruitment of the DNA double-strand break repair factor RAD51 to
chromatin in response to DNA damage.
SLC25A36 AL049246 Solute carrier family 25 (pyrimidine nucleotide carrier),
member 36
To catalyze uptake of pyrimidine (deoxy) nucleotide triphosphates into
the mitochondrial matrix in exchange for internal pyrimidine (deoxy)
nucleotide monophosphates or (deoxy) nucleotide diphosphates.
SNRNP40 AF090988 Small nuclear ribonucleoprotein 40kDa Component of the U5 small nuclear ribonucleoprotein (snRNP)
complex.
SPEN AL096858 Spen family transcriptional repressor Serve as nuclear matrix platform that organizes transcriptional
responses. Essential corepressor protein, which regulates different key
pathways such as the Notch pathway. Represses transcription via the
recruitment of large complexes containing histone deacetylase
proteins.
SRSF4 LI4076 Serine/arginine-rich splicing factor 4 Role in alternative splice site selection during pre-mRNA splicing.
Represses the splicing of MAPT/Tau exon 10.
TAF12 X84002 TATA box binding protein (TBP)-associated factor TAFs are components of the transcription factor IID (TFIID) complex,
PCAF histone acetylase complex and TBP-free TAFII complex (TFTC).
TAFs components-TIIFD are essential for mediating regulation of RNA
polymerase transcription.
TGM2 M55153 Transglutaminase 2 Catalyzes the cross-linking of proteins and conjugation of polyamines
to proteins.
TMEM115 U09584 Transmembrane protein 115 Role in retrograde transport of proteins from the Golgi to the
endoplasmic reticulum.
TOPBP1 D87448 Topoisomerase (DNA) II binding protein 1 Required for DNA replication. Down-regulates E2F1 activity and inhibits
E2F1-dependent apoptosis during G1/S transition and after DNA
damage.
VPS41 U87309 Vacuolar protein sorting 41 Required for vacuolar assembly and vacuolar traffic.
WWC1 AB020676 WW and C2 domain containing 1 Regulator of the Hippo/SWH (Sav/Wts/Hpo) signaling pathway, which
plays a role in tumor suppression by restricting proliferation and
promoting apoptosis. Transcriptional coactivator of ESR1. Regulates
collagen-stimulated activation of the ERK/MAPK cascade.
Gene information was taken from the OMIM database, National Cancer Institute, USA (http://www.ncbi.nlm.nih.gov/Omim/), and from the GeneCard database of the Weizman Institute
of Science, Rehovot, Israel (http://bioinfo.weizmann.ac.il/cards/index.html).
different phytochemicals. In the present study, we analyzed the
cytotoxicity of a combination of two of these phytochemicals
of C. longa, curcumin and AA. If applied alone, curcumin
and AA were cytotoxic toward cell lines of different tumor
types with curcumin exhibiting stronger cytotoxicity than AA.
Our results are in line with other reports on the inhibitory
activity of curcumin (Bimonte et al., 2016; Guzzarlamudi et al.,
2016; Kasi et al., 2016; Ye et al., 2016; Yu et al., 2016;
Zeng et al., 2016) and AA (Chen et al., 2015; Fukui et al.,
2015; Jacobs et al., 2015; Sunil Kumar et al., 2015; Venturelli
et al., 2015). The anticancer effects of curcumin in vitro
and in vivo are primarily due to the activation of apoptotic
pathways in cancer cells as well as the inhibition of mechanisms
related to the tumor microenvironments such as inflammation,
angiogenesis, invasion, and metastasis. In particular, curcumin
targets numerous therapeutically important cancer signaling
pathways such as p53, Ras, PI3K, AKT, Wnt, β-catenin, mTOR,
and so on.
AA also reveals anticancer activity in vitro and in vivo,
however at higher concentration than curcumin. A number of
suggestions have been put forth on the potential mechanisms,
by which AA causes death of cancer cells. The most common is
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TABLE 3 | Meta-data of genes shown in the cluster analysis of whose mRNA expression correlated with log10IC50-values of vitamin C in the NCI tumor
cell line panel.
Gene
symbol
GenBank
acc no.
Gene name Gene function
ABCA1 A1344681 ATP-binding cassette, sub-family A (ABC1),
member 1
cAMP-dependent and sulfonylurea-sensitive anion transporter. Key gatekeeper
influencing intracellular cholesterol transport.
ARHGAP19 U79256 Rho GTPase activating protein 19 GTPase activator for Rho-type GTPases.
CBFB L20298 Core-binding factor, beta subunit CBF binds to enhancers and promoters, including murine leukemia virus,
polyomavirus enhancer, T-cell receptor enhancers, and LCK, IL3, and GM-CSF
promoters.
CD81 M33680 CD81 Regulation of lymphoma cell growth. Involved in signal transduction.
CDK7 X77743 Cyclin-dependent kinase 7 The catalytic subunit of the CDK-activating kinase (CAK) complex.
CRADD U84388 CASP2 and RIPK1 domain containing adaptor
with death domain
Apoptotic adaptor molecule specific for caspase-2 and FASL/TNF
receptor-interacting protein RIP.
DBH X13255 Dopamine beta-hydroxylase (dopamine
beta-monooxygenase)
Conversion of dopamine to noradrenaline.
DIMT1 AF091078 DIM1 dimethyladenosine transferase Dimethylates two adjacent adenosines in the loop of a conserved hairpin near the
3′-end of 18S rRNA in the 40S particle
EED AF080227 Embryonic ectoderm development Transcriptional repression of target genes. Constituent of a recruiting platform for
DNA methyltransferases, thereby involved in epigenetic repression.
FOXG1 X74143 Forkhead box G1 Transcription repression factor.
GRN AF055008 Granulin Cytokine-like activity. Role in inflammation, wound repair, and tissue remodeling.
HDLBP M64098 High density lipoprotein binding protein Role in cell sterol metabolism. Protects cells from over-accumulation of cholesterol.
HMGN1 J02621 High mobility group nucleosome binding
domain 1
Binds to the inner side of the nucleosomal DNA thus altering the interaction between
the DNA and the histone octamer which maintains transcribable genes in a unique
chromatin conformation.
HNRNPR AF000364 Heterogeneous nuclear ribonucleoprotein R Component of ribonucleosomes, which are complexes of >20 other heterogeneous
nuclear ribonucleoproteins (hnRNP). hnRNP play an important role in processing of
precursor mRNA in the nucleus.
HPRT1 M31642 Hypoxanthine phosphoribosyltransferase 1 Transfers 5-phosphoribosyl from 5-phosphoribosylpyrophosphate onto purine.
Generation of purine nucleotides through the purine salvage pathway.
KLHL35 AA471042 Kelch-like family member 35 A protein coding gene.
KNG1 K02566 Kininogen 1 Role in blood coagulation. Inhibits the thrombin- and plasmin-induced aggregation of
thrombocytes.
LRP10 AL080164 Low density lipoprotein receptor-related protein
10
Receptor involved in the internalization of lipophilic molecules and/or signal
transduction. May be involved in the uptake of lipoprotein APOE in liver.
MAP2K2 L11285 Mitogen-activated protein kinase kinase 2 Catalyzes the concomitant phosphorylation of threonine and tyrosine residue in a
Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP
kinases.
MEGF8 AB011541 Multiple EGF-like-domains 8 Encodes a single pass membrane protein which participates in developmental
regulation and cellular communication
NUP160 D83781 Nucleoporin 160 kDa Involved in poly (A)+ RNA transport.
PCMT1 D25547 Protein-L-isoaspartate (D-aspartate)
O-methyltransferase
Catalyzes methyl esterification of L-isoaspartyl and D-aspartyl residues in peptides
and proteins repair and/or degradation of damaged proteins.
PLA2R1 U17034 Phospholipase A2 receptor 1 Receptor for secretory phospholipase A2. Activation of the mitogen-activated protein
kinase (MAPK) cascade to induce cell proliferation, production of lipid mediators, and
selective release of arachidonic acid in bone marrow-derived mast cells. Involved in
responses in proinflammatory cytokine productions during endotoxic shock.
PLAUR X74039 Plasminogen activator, urokinase receptor Role in localizing and promoting plasmin formation. Mediates the
proteolysis-independent signal transduction activation effects of uPA.
PNN U77718 Pinin, desmosome associated protein Transcriptional activator of the E-cadherin gene. Regulation of alternative pre-mRNA
splicing. Regulates specific excision of introns in specific transcription subsets.
Involved in the establishment and maintenance of epithelia cell-cell adhesion.
Potential tumor suppressor for renal cell carcinoma.
PNPLA6 AJ004832 Patatin-like phospholipase domain containing 6 Deacylation of intracellular phosphatidylcholine generating glycerophosphocholine.
PPWD1 D38552 Peptidylprolyl isomerase domain and WD
repeat containing 1
Accelerates the folding of proteins. Involved in pre-mRNA splicing.
(Continued)
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TABLE 3 | Continued
Gene
symbol
GenBank
acc no.
Gene name Gene function
PSAP J03077 Prosaposin Stimulates the hydrolysis of glucosylceramide by beta-glucosylceramidase and
galactosylceramide by beta-galactosylceramidase. Behaves as a myelinotrophic and
neurotrophic factor.
RABAC1 AJ133534 Rab acceptor 1 General Rab protein regulator required for vesicle formation from the Golgi complex.
May control vesicle docking and fusion.
RGS13 AF030107 Regulator of G-protein signaling 13 Inhibits signal transduction by increasing the GTPase activity of G protein alpha
subunits.
SETD4 AB004848 SET domain containing 4 Role in protein encoding.
SI X63597 Sucrase-isomaltase (alpha-glucosidase) Role in the final stage of carbohydrate digestion.
SLC7A2 D29990 Solute carrier family 7 (cationic amino acid
transporter, y+ system), member 2
Transport of cationic amino acids (arginine, lysine and ornithine). Regulatory role in
activation of macrophages.
SMA4 X83300 Glucoridase Required for signal transduction and it also defines a conserved family of transforming
growth factor beta pathway components.
TAF9 U21858 TATA box binding protein (TBP)-associated
factor
Gene regulation associated with apoptosis. Regulation of RNA polymerase
II-mediated transcription.
TCERG1 AF017789 Transcription elongation regulator 1 Transcription factor that binds RNA polymerase II and inhibits the elongation of
transcripts from target promoters in a TATA box-dependent manner.
TFAM M62810 transcription factor A Mitochondrial transcription regulation.
Maintenance of normal levels of mitochondrial DNA. Organizing and compacting
mitochondrial DNA.
TOM1 AJ006973 Target of myb1 Involved in intracellular trafficking. Probable association with membranes.
UBE2N D83004 Ubiquitin-conjugating enzyme E2N The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of
non-canonical “Lys-63”-linked polyubiquitin chains. This type of polyubiquitination
does not lead to protein degradation by the proteasome. Mediates transcriptional
activation of target genes. Plays a role in the control of the cell cycle and
differentiation. Plays a role in the error-free DNA repair pathway and contributes to the
survival of cells after DNA damage. Induction and expression of NF-kappa-B and
MAPK-responsive inflammatory genes.
ZNF195 AF003540 Zinc finger protein 195 May be involved in transcriptional regulation.
Gene information was taken from the OMIM database, National Cancer Institute, USA (http://www.ncbi.nlm.nih.gov/Omim/), and from the GeneCard database of the Weizman Institute
of Science, Rehovot, Israel (http://bioinfo.weizmann.ac.il/cards/index.html).
that AA is a precursor for hydrogen peroxide (H2O2) generation,
which is considered to be preferentially cytotoxic to cancer cells
(Parrow et al., 2013). Exposure to AA concentrations of up to
5 mM for 1 h resulted in decreased survival of cancer cells
and cell death was dependent on H2O2 production mediated
by extracellular AA oxidation (Chen et al., 2005). Furthermore,
intercellular metals contribute to the production of H2O2, with
AA losing an electron to form a radical molecule. The free
electron is donated to a transition metal. This reduced metal is
then available to react with molecular oxygen resulting in the
generation of H2O2. In the presence of AA, H2O2 reacts with
another transition metal ion such as ferrous ion to generate a
hydroxyl radical (Kehrer, 2000). The tumor suppressor p53 may
also play a role for this activity. P53-positive cell lines were more
sensitive to both AA andH2O2 treatment than p53-deficient ones
(Kim et al., 2012).
Thus, having two compounds from one plant with diverse
mechanisms of action, we were interested to evaluate, whether
their combination would reveal synergistic, antagonistic, or
additive interactions. Understanding drug-drug interactions
always represents a critical issue in the drug development process,
since clinically relevant changes in exposure of co-administered
drugs can lead to reduced efficacy or, conversely, adverse
drug reactions, depending on the therapeutic window of the
drugs. The latter becomes especially important with anti-cancer
medications, since they are typically administered at or close to
the maximally tolerated dose (Waters, 2015). In this study, we
applied isobologram analyses to evaluate the nature of interaction
of curcumin and AA. Isobologram analysis is considered as
gold standard to provide evidence for drug interactions. The
combination of curcumin and AA exhibited additive effects in
leukemia and colon cancer cell lines and supra-additive effects in
the glioblastoma cell lines. Our hypothesis is that both natural
products may work together by different molecular pathways to
achieve their overall cytotoxicity. Unlike chemically synthesized
drugs, natural products might be active at lower doses and over
longer periods of incubation, which could further support the
appearance of additive effects.
We further analyzed molecular determinants of sensitivity
and resistance of cancer tumor cell lines toward curcumin and
AA. We correlated the IC50-values expressed on induction by
curcumin and AA of 60 tumor cell lines by COMPARE analysis of
microarray-based transcriptome-wide mRNA expression levels
of these cell lines (Scherf et al., 2000). We identified genes from
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FIGURE 6 | Dendrograms and cluster image map of curcumin obtained by hierarchical cluster analysis of mRNA expression of 40 genes in the NCI cell
line panel as analyzed by the Novartis microarray platform. The dendrogram on the left shows the clustering of cell lines and the dendrogram on the top shows
the clustering of genes. The cluster image map shows each single mRNA expression value obtained by microarray analysis. The expression values have been
normalized and color-coded.
diverse functional groups, which were associated with response
of the tumor cells toward curcumin and AA. Under curcumin
treatment, these groups of genes included DNA repair, mRNA
metabolism, signal transduction, angiogenesis, proliferation,
apoptosis etc. While for AA treatment, the COMPARE analysis
provided genes that are involved in signal transduction,
Frontiers in Pharmacology | www.frontiersin.org 11 February 2017 | Volume 8 | Article 38
Ooko et al. Combination Treatment of Vitamin C and Curcumin
FIGURE 7 | Dendrograms and cluster image map of vitamin C obtained by hierarchical cluster analysis of mRNA expression of 40 genes in the NCI cell
line panel as analyzed by the Novartis microarray platform. The dendrogram on the left shows the clustering of cell lines and the dendrogram on the top shows
the clustering of genes. The cluster image map shows each single mRNA expression value obtained by microarray analysis. The expression values have been
normalized and color-coded.
transcription factors, and apoptosis. Although the exact function
of these genes for cellular responsiveness to curcumin or AA
treatment is still unknown, we have some clues of explanation.
On treatment with AA the following genes were downregulated:
SETD4, TAF9, PNN, CDK7, TFAM, and PPWD1. SETD4 is
a methyltransferase, which is involved in carcinogenesis. Its
down-regulation suppressed cellular proliferation and delayed
the G1/S cell cycle transition without affecting apoptosis.
Furthermore, its knockdown decreased cyclin D1 (Faria et al.,
2013). The TATA-binding protein associated factor 9 (TAF9)
interacts with oncogenic GLI family members to form GLI-
TAF9 binding, which is important for carcinogenesis activity and
malignant growth (Yoon et al., 2015). PNN is a nuclear and cell
adhesion-related protein participating in the regulation of gene
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TABLE 4 | Separation of clusters of NCI cell lines obtained by hierarchical
cluster analyses for curcumin (Figure 6) or ascorbic acid (Figure 7).
Sensitive Resistant
CURCUMIN
Partition <–5.1 M ≥−5.1 M
Cluster1 0 4
Cluster2 5 11
Cluster3 16 3
Cluster4 10 8
Cluster5 1 1
Chi-square test P = 4.59 * 10−3
ASCORBIC ACID
Partition <−2.7 M ≥−2.7 M
Cluster 1 2 0
Cluster 2 5 14
Cluster 3 12 20
Cluster 4 0 6
Chi-square P = 0.050
The median log10 IC50-values (–5.1 M for curcumin and –2.7 M for ascorbic acid) were
used as cut-off to separate tumor cell lines as being “sensitive” or “resistant.”
expression and thereby, positively promoting cell-cell adhesion,
and negatively affecting cell migration and cell proliferation
(Shi et al., 2001). Cyclin-dependent kinase 7 (CDK7), which
promotes transcription during the cell cycle, is critical for the
survival of cancer cells. The inhibition of CDK7 suppressed
proliferation and induced apoptotic cell death (Wang et al.,
2015). Mitochondrial transcription factor A (TFAM), a member
of the highmobility group (HMG) box protein family, is required
for mitochondrial DNA replication and transcription. HMG
proteins are often overexpressed in cancer cells and are involved
in apoptosis regulation (Krynetskaia et al., 2009; Vander Heiden
et al., 2009). TFAM may play a significant role in tumorigenesis
(Guo et al., 2011). PPWD1 has a well-characterized peptide
domain (WD40 domain for PPWD1), and this domain has also
a critical role in carcinogenesis. The WD40 domain mediates
signal transduction and transcriptional regulation during cell
cycle and apoptosis. PPWD1 may serve as target for drug
development (Davis et al., 2008; Jeon et al., 2014). From the above
discussion, AA mechanism revolves around the genes affecting
cell proliferation and cell cycle events; it can be assumed that
these genes contribute to sensitivity of the tumor cells to AA.
On the other hand, genes potentially responsible for
responsiveness on curcumin treatment were identified and
curcumin downregulated, i.e., AK2, PDK1, NR2F2, DFFB,
MTHFD2, and ALDH3B1. Adenylate kinases (AKs) represent
enzymes that catalyze reversible high-energy phosphoryl transfer
reactions between adenine nucleotides in the intermembrane
space. During periods of metabolic stress, AK2 increases the
amount of available adenosine monophosphate and therefore
activates downstream ATP-sensing mechanisms—such as AMP-
activated protein kinase (AMPK)—to regulate the cellular
metabolism. Inhibition of AK2 expression significantly inhibited
the proliferation of cancer cells (Dzeja and Terzic, 2009). PDK1
plays a key role in several cancer types. Alterations of PDK1
are critical for oncogenic PI3K signaling. PDK1 has an essential
role in regulating cell migration, especially in the context
of PTEN deficiency. Downregulation of PDK1 levels inhibits
migration and metastasis. PDK1 inhibitors may be useful to
prevent cancer progression and abnormal tissue dissemination
(Raimondi and Falasca, 2011). The nuclear receptor subfamily 2,
group F, member 2 (NR2F2) is a master regulator of angiogenesis
and acts as oncogene in prostate and other human cancers.
NR2F2 is robustly expressed in the stroma of healthy ovary with
little or no expression in epithelia lining the ovarian surface,
clefts, or crypts. The pattern of NR2F2 expression was severely
disrupted in ovarian cancers, in which decreased levels of stromal
expression and ectopic epithelial expression were exhibited.
TargetingNR2F2 expression in ovarian cancer cell lines enhanced
apoptosis and increased proliferation (Hawkins et al., 2013).
DFFB contributes to both chromosomal condensation and
DNA degradation during apoptosis, decreased DFFB expression
favors DNA damage, which in turn may contribute to
both tumorigenesis and better response to DNA damaging
chemotherapy (McDonald et al., 2005). MTHFD2 mRNA and
protein expression is markedly elevated in many cancers and
correlated with poor survival in breast cancer. MTHFD2 is
integral to mitochondrial one-carbon metabolism, a metabolic
system recently implicated in rapid cancer cell proliferation.
Synthesis of one-carbon units carried by the tetrahydrofolate
(THF) cofactor is important for proliferating cells, required for
nucleotide synthesis and methylation reactions. MTHFD2 is a
bifunctional enzyme, catalyzing the NAD+ dependent CH2-THF
dehydrogenase and CH+-THF cyclohydrolase reactions within
the mitochondria. Within the mitochondrial folate pathway,
MTHFD2 is of special interest, because MTHFD2 was one of
themost consistently overexpressedmRNAs genome-wide across
19 different tumor types. The MTHFD2 protein is specifically
expressed in transformed cells, but not the stroma surrounding
the tumor tissues. MTHFD2 by RNAi impairs proliferation
in a variety of cancer cell lines, independent of the tissue
of origin, and decreases invasion and migration in breast
cancer cell lines. MTHFD2 is broadly required for cancer cell
proliferation and viability (Lehtinen et al., 2013; Nilsson et al.,
2014). ALDH3B1 is a metabolically active enzyme with distinct
specificity for various aldehyde substrates, particularly medium-
, and long-chain aliphatic aldehydes. These substrates include
many products that are formed during LPO, such as hexanal,
4-hydroxy-2-nonenal (4-HNE), octanal, and trans-2-nonenal.
ALDH3B1 plays an important physiological role against cellular
oxidative stress by detoxifying aldehydes derived from oxidative
processes, such as ethanol metabolism and LPO (Marchitti et al.,
2010). Our pharmacogenomics data shows curcumin suppressing
cell proliferation by downregulation of anti-apoptotic genes and
cell surface adhesionmolecules. Curcumin is also seen to regulate
cellular metabolism and inhibition of angiogenic cytokines.
We can then suggest that the downregulated genes affect the
sensitivity of the tumor cells to curcumin.
Previously, we reported the mRNA expression profile induced
by curcumin in the NCI cell line panel, which was merged
from four different microarray platforms (Novartis, Stanford,
Chiron, and Genelogic; Sertel et al., 2012). In the present
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investigation, we focused only on the Novartis microarray
platform for the comparison of curcumin and vitamin C and
to reduce the degree of complexity. If we compared the top
ranked genes in the previous analysis with those of the present
investigation, we found some genes in common (MTHFD2, AK2,
NFATC21P, BTAF1, RBBP4), although the majority of genes were
different in both analyses. This result points to an observation
that was frequently made by many investigators: different
microarray platforms deliver different results. Nevertheless,
several biological functional groups were found to be common in
our previous and the present paper, e.g. cell cycle, DNA damage
response, cell migration, inflammation, signaling pathways, and
apoptosis-regulating genes. To our opinion, microarray data
are reliable, if they are used for the generation of testable
hypotheses. In this respect, both of our microarray analyses
were useful. Microarray data represents the starting point for the
elucidation of modes of action of cytotoxic compounds rather
than completed end results.
Cluster analyses were applied in the present investigation
under the assumption that responsiveness of cancer cells might
be predicted by using gene expression patterns and that
appropriate gene expression profiles might be sufficient to predict
whether a cancer cell line is sensitive or resistant to a cytotoxic
compound (Sertel et al., 2010). Curcumin revealed two clusters
with predominantly sensitive and three with predominantly
resistant cell lines. For AA cluster analysis revealed two clusters
containing mainly resistant and two clusters containing mainly
sensitive cell lines in a comparable fashion to curcumin. The
prediction of sensitivity or resistance to cytotoxic drugs by
mRNA expression profiles is interesting in the context of
individualized or precision medicine, because it may open the
possibility to determine prior to treatment, whether or not a
tumor will respond to specific drugs. Our data demonstrate that
this may not only be feasible to established anticancer drugs, but
also to investigative natural products such as curcumin or AA.
The fact that the mRNA expression profiles induced by
curcumin and AA related to different gene expression patterns
may be related to different modes of actions of both compounds.
Medicinal herbs generally containmixtures of active compounds,
which may interact in an additive or synergistic manner.
Synergistic interactions may need common mechanisms e.g., a
common specific pathway that they inhibit. From an evolutionary
point of view, synergistic interactions need co-evolutionary
selection pressures to evolve. Hence, it can be speculated that
synergisms are less likely to occur than additive effects. Therefore,
additive drug interactions can be more frequently found in
medicinal herbs. Compounds with different modes of action
can efficiently and sufficiently fulfill the requirements for plants
to survive under specific evolutionary selection pressure. This
may explain that we found additive rather than synergistic
interactions in isobologram analyses between curcumin and
AA in the panel of cell lines tested. This observation is in
accordance with previous data with several cytotoxic compounds
from Artemisia annua L., which also showed additive rather than
synergistic interactions (Efferth et al., 2011).
In summary, we have identified some genes which were
downregulated by AA and curcumin. The genes may be
responsible for cellular responsiveness of the varied cancer cells
to AA and curcumin treatments. The cellular activities tackled by
the downregulated genes include inhibition of cell proliferation
and cell cycle activities, reduction in cellular metabolism,
downregulation of anti-apoptotic gene products and inhibition
of angiogenic cytokines. The two natural products seem to induce
cytotoxicity by different mechanisms and this may lead to achieve
tumor eradication in vivo. The varied cellular functionalities
represented by the genes downregulated may support additive
effects observed in the isobologram analyses.
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